First Time Loading...

Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 14.3 USD 0.42% Market Closed
Updated: Apr 18, 2024

Intrinsic Value

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. [ Read More ]

The intrinsic value of one URGN stock under the Base Case scenario is 18.83 USD. Compared to the current market price of 14.3 USD, Urogen Pharma Ltd is Undervalued by 24%.

Key Points:
URGN Intrinsic Value
Base Case
18.83 USD
Undervaluation 24%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Urogen Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling URGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Urogen Pharma Ltd

Provide an overview of the primary business activities
of Urogen Pharma Ltd.

What unique competitive advantages
does Urogen Pharma Ltd hold over its rivals?

What risks and challenges
does Urogen Pharma Ltd face in the near future?

Has there been any significant insider trading activity
in Urogen Pharma Ltd recently?

Summarize the latest earnings call
of Urogen Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Urogen Pharma Ltd.

Provide P/S
for Urogen Pharma Ltd.

Provide P/E
for Urogen Pharma Ltd.

Provide P/OCF
for Urogen Pharma Ltd.

Provide P/FCFE
for Urogen Pharma Ltd.

Provide P/B
for Urogen Pharma Ltd.

Provide EV/S
for Urogen Pharma Ltd.

Provide EV/GP
for Urogen Pharma Ltd.

Provide EV/EBITDA
for Urogen Pharma Ltd.

Provide EV/EBIT
for Urogen Pharma Ltd.

Provide EV/OCF
for Urogen Pharma Ltd.

Provide EV/FCFF
for Urogen Pharma Ltd.

Provide EV/IC
for Urogen Pharma Ltd.

Show me price targets
for Urogen Pharma Ltd made by professional analysts.

What are the Revenue projections
for Urogen Pharma Ltd?

How accurate were the past Revenue estimates
for Urogen Pharma Ltd?

What are the Net Income projections
for Urogen Pharma Ltd?

How accurate were the past Net Income estimates
for Urogen Pharma Ltd?

What are the EPS projections
for Urogen Pharma Ltd?

How accurate were the past EPS estimates
for Urogen Pharma Ltd?

What are the EBIT projections
for Urogen Pharma Ltd?

How accurate were the past EBIT estimates
for Urogen Pharma Ltd?

Compare the revenue forecasts
for Urogen Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Urogen Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Urogen Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Urogen Pharma Ltd compared to its peers.

Compare the P/E ratios
of Urogen Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Urogen Pharma Ltd with its peers.

Analyze the financial leverage
of Urogen Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Urogen Pharma Ltd.

Provide ROE
for Urogen Pharma Ltd.

Provide ROA
for Urogen Pharma Ltd.

Provide ROIC
for Urogen Pharma Ltd.

Provide ROCE
for Urogen Pharma Ltd.

Provide Gross Margin
for Urogen Pharma Ltd.

Provide Operating Margin
for Urogen Pharma Ltd.

Provide Net Margin
for Urogen Pharma Ltd.

Provide FCF Margin
for Urogen Pharma Ltd.

Show all solvency ratios
for Urogen Pharma Ltd.

Provide D/E Ratio
for Urogen Pharma Ltd.

Provide D/A Ratio
for Urogen Pharma Ltd.

Provide Interest Coverage Ratio
for Urogen Pharma Ltd.

Provide Altman Z-Score Ratio
for Urogen Pharma Ltd.

Provide Quick Ratio
for Urogen Pharma Ltd.

Provide Current Ratio
for Urogen Pharma Ltd.

Provide Cash Ratio
for Urogen Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Urogen Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Urogen Pharma Ltd?

What is the current Free Cash Flow
of Urogen Pharma Ltd?

Financials

Balance Sheet Decomposition
Urogen Pharma Ltd

Current Assets 169.2m
Cash & Short-Term Investments 137m
Receivables 15.4m
Other Current Assets 16.8m
Non-Current Assets 9.1m
Long-Term Investments 4.5m
PP&E 2.4m
Other Non-Current Assets 2.3m
Current Liabilities 31.2m
Accounts Payable 6.5m
Accrued Liabilities 21.7m
Other Current Liabilities 3m
Non-Current Liabilities 212.3m
Long-Term Debt 98.6m
Other Non-Current Liabilities 113.8m
Efficiency

Earnings Waterfall
Urogen Pharma Ltd

Revenue
82.7m USD
Cost of Revenue
-9.4m USD
Gross Profit
73.4m USD
Operating Expenses
-138.9m USD
Operating Income
-65.5m USD
Other Expenses
-36.7m USD
Net Income
-102.2m USD

Free Cash Flow Analysis
Urogen Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

URGN Profitability Score
Profitability Due Diligence

Urogen Pharma Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
43/100
Profitability
Score

Urogen Pharma Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

URGN Solvency Score
Solvency Due Diligence

Urogen Pharma Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
53/100
Solvency
Score

Urogen Pharma Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

URGN Price Targets Summary
Urogen Pharma Ltd

Wall Street analysts forecast URGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for URGN is 39.27 USD with a low forecast of 18.18 USD and a high forecast of 56.7 USD.

Lowest
Price Target
18.18 USD
27% Upside
Average
Price Target
39.27 USD
175% Upside
Highest
Price Target
56.7 USD
297% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

URGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

URGN Price
Urogen Pharma Ltd

1M 1M
-1%
6M 6M
+23%
1Y 1Y
+50%
3Y 3Y
-22%
5Y 5Y
-61%
10Y 10Y
+10%
Annual Price Range
14.3
52w Low
8.84
52w High
22.64
Price Metrics
Average Annual Return -28.2%
Standard Deviation of Annual Returns 19.8%
Max Drawdown -87%
Shares Statistics
Market Capitalization 464.6m USD
Shares Outstanding 34 122 100
Percentage of Shares Shorted 13.28%

URGN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Urogen Pharma Ltd Logo
Urogen Pharma Ltd

Country

Israel

Industry

Biotechnology

Market Cap

464.6m USD

Dividend Yield

0%

Description

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Contact

Ra'anana
9 Ha'ta'asiya St
+97297707601.0
https://www.urogen.com/

IPO

2017-05-04

Employees

195

Officers

President, CEO & Director
Ms. Elizabeth A. Barrett
Chief Financial Officer
Mr. Dong Kim
General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. Jason Drew Smith
Senior Director of Investor Relations
Vincent I. Perrone
Executive Vice President of Talent, Advocacy & Communications
Mr. Bryon Wornson
Marketing Director
Dr. Sari Prutchi-Sagiv Ph.D.
Show More
Executive Vice President of Research & Development and Technical Operations
Dr. Marina Konorty
Chief Medical Officer
Dr. Mark P. Schoenberg M.D.
Chief Commercial Officer
Mr. Jeffrey Bova M.B.A.
Executive Vice President of Regulatory Affairs & Quality
Mr. James Ottinger R.ph.
Show Less

See Also

Discover More
What is the Intrinsic Value of one URGN stock?

The intrinsic value of one URGN stock under the Base Case scenario is 18.83 USD.

Is URGN stock undervalued or overvalued?

Compared to the current market price of 14.3 USD, Urogen Pharma Ltd is Undervalued by 24%.